Skip to content

CeriBell, Inc. CBLL Current ratio

Current ratio at other companies

IAR
Integra LifeSciencesIART
3.4×+2.2×
ClearPoint Neuro logo
ClearPoint NeuroCLPT
5.8×+2.3×
iRadimed logo
iRadimedIRMD
7.1×-1.7×
Teladoc Health logo
Teladoc HealthTDOC
2.8×+1.1×
Kestra Medical Technologies, Ltd. Common Stock logo
Kestra Medical Technologies, Ltd. Common StockKMTS
7.3×
Cerence Inc. logo
Cerence Inc.CRNC
1.9×+0.4×

Other financials

Income statement

See full
Revenue$26.5M+29.3%
Gross profit$23.1M+28.4%
Operating income-$20.7M-46.0%
Net income-$19.7M-54.5%
EPS (diluted)-$0.52-44.4%

Balance sheet

See full
Cash & equivalents$45.3M-70.5%
Total debt$22.1M+1.6%
Total equity$140.8M-22.2%
Total assets$178.1M-16.6%

Cash flow

See full
Operating cash flow-$19.3M-69.2%
CapEx$125.0K-15.5%
Free cash flow-$19.4M-68.1%

Valuation

See full
Market cap$748.61M+15.6%
Enterprise value$725.47M+40.7%
P/S7.9×-1.2×

Profitability

See full
Gross margin87.7%+0.5pp
Operating margin-68.3%+5.5pp
Net margin-63.5%+1.0pp
FCF margin-52%-1.4pp

Returns & leverage

See full
Return on equity-37.5%
Debt / equity0.2×0.0×

Where this comes from

Calculated from CeriBell, Inc.’s reported figures.

Based on the most recent quarter.

The official record: CeriBell, Inc.’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →

Ask your AI about CeriBell, Inc.'s current ratio.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is CeriBell, Inc.'s current ratio?
CeriBell, Inc. (CBLL) reported current ratio of 10.4× in Q1 2026.
How has CeriBell, Inc.'s current ratio changed year-over-year?
CeriBell, Inc.'s current ratio decreased by 39.9% year-over-year, from 17.4× to 10.4×.
What is the long-term trend for CeriBell, Inc.'s current ratio?
Over 2 years (2023 to 2025), CeriBell, Inc.'s current ratio has grown at a 101.1% compound annual growth rate (CAGR), from 2.4× to 9.7×.
What does current ratio mean?
Current assets divided by current liabilities at the quarter end. Measures the company's ability to cover near-term obligations with near-term assets.